---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000033"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:22:48.506867+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech presents long-term B-VEC data showing durable wound healing in DEB patients

## Summary
- DDEB patient treated >2 years and RDEB patient >3 years with weekly topical B-VEC.
- RDEB patient's wound burden decreased 80-90%, reverted from severe to intermediate generalized phenotype.
- No significant adverse events attributed to B-VEC; treatment well tolerated.
- RDEB patient showed systemic improvements: increased height, weight, and serum albumin levels.
- Data presented at ISID meeting in Tokyo, May 2023.

## SEC filing metadata
- accession: 0001711279-23-000033
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000033/0001711279-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000033/krys-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000033
- JSON: https://secwatch.observer/filing/0001711279-23-000033.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.